For research use only. Not for therapeutic Use.
Fadrozole (CAT: I011409) is a nonsteroidal aromatase inhibitor that is primarily used in the treatment of estrogen-dependent breast cancer. Aromatase is an enzyme that converts androgens into estrogens, and inhibiting this enzyme can help reduce estrogen levels in the body. By blocking aromatase, fadrozole reduces estrogen production and subsequently inhibits the growth of hormone receptor-positive breast cancer cells. It is typically administered orally and has shown efficacy in both early-stage and advanced breast cancer cases.
Catalog Number | I011409 |
CAS Number | 102676-47-1 |
Synonyms | 4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile; |
Molecular Formula | C14H13N3 |
Purity | ≥95% |
Target | Cytochrome P450 |
Storage | RT |
Related CAS | 102676-31-3(hydrochloride) |
Reference | 1: Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A. Fadrozole |